Article Details - Overview
Emerging Therapeutic Options in Midgut Neuroendocrine Tumors
Oncology Briefings Vol. 7, No. 5
Release Date: August 27, 2009
Expiration Date: August 27, 2010
Publication Overview
Authors
Medical writer: Timothy Quill, PhD; Reviewed by: Rudolf Arnold, MD, FRCP
Overview and Purpose
Midgut neuroendocrine, or carcinoid, tumors are the most common subtype of gastrointestinal neuroendocrine tumors (NETs) and a common cause of isolated hepatic metastases. These tumors secrete a variety of neuropeptides and hormones that can cause incapacitating symptoms in patients with metastatic disease. Both somatostatin analogues and interferon are used to control these symptoms, but the effect is transient, and NETs remain incurable and resistant to cytotoxic chemotherapy. More recent evidence, however, indicates that somatostatin analogues can delay disease progression. In addition, novel somatostatin analogues are currently being evaluated as therapy for NETs. Targeted agents are also being investigated in patients with advanced NETs based on an evolving molecular understanding of tumor characteristics. Antiangiogenic agents have demonstrated promising effects on these highly vascular tumors in early-stage trials. In addition, an inhibitor of the mammalian target of rapamycin kinase has demonstrated antitumor activity in patients with advanced NETs in early-stage trials.
The purpose of this activity is to inform oncologists of new developments in the use of targeted therapies in the treatment of patients with midgut NETs.
Target Audience
Target Audience
This educational activity is intended for medical oncologists involved in the care of patients with midgut NETs. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Discuss the biology of midgut NETs and the rationale for targeting novel signaling pathways
- Assess the efficacy and safety of somatostatin analogue therapy in the treatment of patients with advanced/metastatic midgut NETs
- Evaluate the role of novel targeted approaches, such as antiangiogenic therapy, in the treatment of patients with midgut NETs
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
The tests and evaluation must be completed by August 27, 2010, in order for you to receive your certificate.
You will be asked to login
or create an account.